Inozyme Pharma, Inc. - INZY STOCK NEWS

Inozyme Pharma announced positive topline results from its Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 deficiencies. Results showed a significant increase in plasma pyrophosphate (PPi) across all dose cohorts, with normal levels sustained in the highest dosage. Patient-reported outcomes indicated improvements in health for the majority of participants. INZ-701 was well-tolerated, showing a favorable safety profile with no serious adverse events. The company expects its cash reserves to fund operations into the fourth quarter of 2024, enhancing its clinical development pathway.

Inozyme Pharma (Nasdaq: INZY) will host an Investor and Analyst Event on February 16, 2023, at 8 a.m. ET to discuss topline data from its ongoing Phase 1/2 trials of INZ-701 targeting ENPP1 and ABCC6 Deficiency. The event will feature key opinion leaders, including Michael Levine, Wilko Spiering, and Mark Kiel, who will discuss the therapeutic implications and development milestones of INZ-701. This clinical trial aims to demonstrate the safety, tolerability, and pharmacokinetics of INZ-701 in patients affected by these rare conditions, for which there are currently no approved therapies.

Inozyme Pharma (Nasdaq: INZY) will present topline data from its ongoing Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 Deficiencies during a virtual event on February 16, 2023. In 2022, the company reported significant advancements in both programs, including evidence of INZ-701's impact on pyrophosphate (PPi) levels, crucial for mineralization regulation. The trials are aimed at evaluating safety, pharmacokinetics, and pharmacodynamics of INZ-701, with previous positive results noted in both trials. The event will feature presentations from Inozyme's management and key opinion leaders.

Inozyme Pharma (Nasdaq: INZY) announced a groundbreaking study revealing the genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies—more than tripling previous estimates. The research estimates a global patient population of 37,000, including 2,800 in North America, 4,100 in Europe, and 900 in Japan. The study highlights an urgent need for therapies as many affected individuals remain undiagnosed. The company is developing INZ-701, an enzyme therapy currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies.

Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, has announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on December 8, 2022, from 8:00-8:30am ET. The event will showcase insights into the company’s work on novel therapeutics, particularly INZ701, a potential first-in-class enzyme therapy for pathologic mineralization and intimal proliferation.
A replay will be available on their website after the event.

Inozyme Pharma reported financial results for Q3 2022, highlighting ongoing Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 deficiencies. Dosing is underway in the third cohort for both trials, with topline data expected in Q4 2022 and Q1 2023, respectively. The cash position stood at $141.5 million, sufficient to fund operations into Q2 2024. R&D expenses increased to $12.2 million due to trial progress, while G&A expenses slightly decreased. The net loss was $16.4 million, or $0.38 per share, compared to $14.3 million, or $0.60 per share, a year ago.

Inozyme Pharma, Inc. (Nasdaq: INZY), a biopharmaceutical company focused on treating rare diseases, announced CEO Axel Bolte's participation in two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 17, from 9:10-9:40am GMT. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, from 12:30-12:55pm ET. Inozyme is developing INZ-701, a potential first-in-class enzyme therapy, currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies, addressing serious diseases linked to pathologic mineralization.

Inozyme Pharma (Nasdaq: INZY) announced the self-administration of INZ-701 in the Phase 2 extension of its ongoing Phase 1/2 clinical trial for ENPP1 Deficiency. This milestone is backed by FDA and BfArM protocol amendments, highlighting INZ-701’s safety profile. INZ-701, a promising enzyme therapy for rare diseases, will allow patients to self-administer post a 32-day clinical dose evaluation. The trial aims to assess long-term safety and effectiveness, potentially making INZ-701 the first approved therapy for ENPP1 Deficiency, a serious condition with currently no approved treatments.

Inozyme Pharma (Nasdaq: INZY) announced a peer-reviewed publication in Human Mutation revealing a 3-fold increase in pathogenic/likely pathogenic ENPP1 variants. The study identified 109 unique ENPP1 variants, 79 of which are pathogenic, and highlighted the absence of genotype-phenotype correlation. This suggests that the population affected by ENPP1 Deficiency is larger than previously estimated, with potential therapeutic options for those with heterozygous mutations. Inozyme continues to develop INZ-701 to treat this rare disease.